midazolam has been researched along with Androgen-Independent Prostatic Cancer in 2 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Midazolam was administered as phenotyping probe for cytochrome P450 isoenzyme 3A (CYP3A)." | 1.46 | Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer. ( Bloemendal, HJ; Janssen, A; Mathijssen, RHJ; Ter Heine, R; van der Vlist, A; Verkleij, CPM, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Janssen, A | 1 |
| Verkleij, CPM | 1 |
| van der Vlist, A | 1 |
| Mathijssen, RHJ | 1 |
| Bloemendal, HJ | 1 |
| Ter Heine, R | 1 |
| Gibbons, JA | 1 |
| de Vries, M | 1 |
| Krauwinkel, W | 1 |
| Ohtsu, Y | 1 |
| Noukens, J | 1 |
| van der Walt, JS | 1 |
| Mol, R | 1 |
| Mordenti, J | 1 |
| Ouatas, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Open-label Study to Evaluate the Effect of Multiple Doses of MDV3100 (ASP9785) on the Pharmacokinetics of Substrates for CYP2C8, CYP2C9, CYP2C19, and CYP3A4 in Patients With Castration-resistant Prostate Cancer[NCT01911728] | Phase 1 | 14 participants (Actual) | Interventional | 2011-07-25 | Completed | ||
| A Phase I Randomized, Open-label, 3-arm Parallel-design Study to Determine the Effect of Multiple-dose Gemfibrozil or Itraconazole on the Pharmacokinetics, Safety and Tolerability of Single-dose MDV3100 (ASP9785) in Healthy Male Subjects[NCT01913379] | Phase 1 | 41 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for midazolam and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Pharmacokinetic Drug Interaction Studies with Enzalutamide.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cross-Over Studies; Cytochrome P-450 CYP2C8 Inhibitors; | 2015 |
Pharmacokinetic Drug Interaction Studies with Enzalutamide.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cross-Over Studies; Cytochrome P-450 CYP2C8 Inhibitors; | 2015 |
Pharmacokinetic Drug Interaction Studies with Enzalutamide.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cross-Over Studies; Cytochrome P-450 CYP2C8 Inhibitors; | 2015 |
Pharmacokinetic Drug Interaction Studies with Enzalutamide.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cross-Over Studies; Cytochrome P-450 CYP2C8 Inhibitors; | 2015 |
1 other study available for midazolam and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer.
Topics: Aged; Anti-Anxiety Agents; Antineoplastic Agents; Body Surface Area; Carcinoma; Cytochrome P-450 CYP | 2017 |